CURE^® San Antonio Breast Cancer Symposium Conference Report

December 12, 2020

Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.

December 11, 2020

In this phase 3 trial, Verzenio with endocrine therapy reduced the risk for invasive disease recurrence and death versus endocrine therapy alone for patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

December 10, 2020

Prior to receiving behavioral interventions, more than half of participating young survivors of breast cancer were considered clinically depressed. That number dropped to 30% after participants received mindfulness meditation and survivorship education classes.

December 10, 2020

Women with higher diet adherence scores after diagnosis had a 33% lower risk for all-cause mortality and a 17% lower risk for mortality related to breast cancer compared with women with lower diet adherence scores.

December 10, 2020

Of note, the results indicated that patients with breast cancer who were younger than 60 and of Black or other race were more likely to experience under-recognized symptoms by their physician.

December 09, 2020

Younger age, breast cancer diagnosis, Medicaid insurance and treatment type were associated with an increased risk for women becoming new chronic users of opioids or sedatives/hypnotics following mastectomy with reconstructive surgery.